Close

Vyvanse® Chewable Tablet added to Ontario Formulary

Vyvanse® (lisdexamfetamine dimesylate) chewable tablet will be publically reimbursed in Ontario for ADHD treatment from March 31, 2020 for individuals (6 years and older) who require 12-hour continuous coverage due to academic and/or psychosocial needs, under these circumstances: Patients demonstrate significant and problematic disruptive behaviour or who problems with inattention that interfere with learning; AND…

Strategic alliance will improve health of patients suffering from ADHD by providing greater access to resources ‘at the point of care™

March 24, 2020 – Toronto, Ontario The Centre for ADHD Awareness, Canada (CADDAC), announced today a strategic alliance with iMD Health Global that will help evolve communications between healthcare professionals and patients to improve health outcomes, focused on ADHD (Attention Deficit Hyperactivity Disorder).  iMD Health offers innovative technology that facilitates meaningful dialogue between healthcare professionals…